The company
Guardant Health, Inc.
GH · Nasdaq
Health CareDiagnostics & LabsLeading
GH stood above a rising 150-day average in 44 of the last 52 weekly readings, including each of the last 23 weeks. It is 22.8% above that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+2 points in four weeks); Health Care: 27% (−6 points in four weeks).
Statistics
- Last close, 23 Oct 2026
- 169.08 +3.77%
- 52-week range
- —
- Volume
- 1.67M
- Average volume (50 days)
- —
- Relative volume
- —
- Rotation
- Leading
- Weeks in an uptrend
- 23 in a row
- Industry in uptrend
- 52% +2 in 4 wk
- Insider buys, 12 months
- $157K
- Insider sales, 12 months
- $303.1M
- Officials’ trades on record
- 12
- Institutions holding
- 554 (+100)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.
24 Apr – 23 Oct
Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Price and volume
close
Daily bars to 23 Oct 2026: 30 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
12 disclosed lines: House 11, Senate 1, executive 0; 3 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Jonathan L. Jackson House: U.S. House ClerkIL01 | boughtjoint | $15k–$50k | 28 Sep 2026filed 19 Oct 2026 |
| Sheldon Whitehouse Senate: U.S. Senate eFDSenator | bought | $1k–$15k | 21 Nov 2025filed 1 Dec 2025 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 28 Feb 2022filed 3 Mar 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 13 Jan 2022filed 1 Feb 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 22 Dec 2021filed 1 Jan 2022 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 2 Nov 2020filed 1 Dec 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 22 Oct 2020filed 5 Nov 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | boughtjoint | $1k–$15k | 5 Oct 2020filed 5 Nov 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 14 Jul 2020filed 9 Aug 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | soldjoint | $1k–$15k | 1 May 2020filed 31 May 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | sold | $1k–$15k | 27 Apr 2020filed 9 May 2020 |
| Donald S. Beyer, Jr. House: U.S. House ClerkVA08 | bought | $1k–$15k | 14 Feb 2020filed 22 Feb 2020 |
Insiders
Buy orders, 12 months1
Sale orders, 12 months58
Buyers · sellers1 · 15
| Who | Did | Shares | Traded |
|---|---|---|---|
| Musa TariqDirector | sold | 116at $165.88 | 16 Oct 2026filed 19 Oct 2026 |
| Alex M. Azar IIDirector | sold | 69at $159.89 | 14 Oct 2026filed 15 Oct 2026 |
| Alex M. Azar IIDirector | sold | 826at $175.00 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 1,103at $174.46 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 3,300at $175.42 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 1,300at $176.34 | 16 Sep 2026filed 17 Sep 2026 |
| Steve E. KrognesDirector | sold | 971at $177.48 | 16 Sep 2026filed 17 Sep 2026 |
| Musa TariqDirector | sold | 116at $175.00 | 16 Sep 2026filed 17 Sep 2026 |
| Darya ChudovaChief Technology Officer | sold | 7,738at $178.00 | 15 Sep 2026filed 17 Sep 2026 |
| Kumud KaliaChief Information Officer | sold | 4,000at $158.05 | 11 Sep 2026filed 14 Sep 2026 |
| Amirali TalasazCo-Chief Executive Officer | sold | 9,023at $168.20 | 21 Aug 2026filed 24 Aug 2026 |
| Amirali TalasazCo-Chief Executive Officer | sold | 20,888at $169.16 | 21 Aug 2026filed 24 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders554+100 on the quarter
New · exited148 · 47
Reported value$18.7B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 7,622,935$1.1B | -3,930,824−34.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 5,755,857$863.6M | +131,677+2.3% |
| FMR LLCadded · filed 13 Aug 2026 | 5,488,272$823.4M | +1,372,191+33.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 5,445,785$817.0M | -392,207−6.7% |
| Invesco Ltd.reduced · filed 14 Aug 2026 | 4,429,755$664.6M | -516,714−10.4% |
| GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 2026 | 3,775,895$566.5M | -659,944−14.9% |
| TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026 | 3,719,301$558.0M | -510,230−12.1% |
| Capital International Investorsreduced · filed 12 Aug 2026 | 3,399,604$510.0M | -81,714−2.3% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 3,393,312$509.1M | +55,071+1.6% |
| FRANKLIN RESOURCES INCreduced · filed 13 Aug 2026 | 3,236,065$485.5M | -212,128−6.2% |
31 Mar 2023 – 30 Jun 2026
News
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 - Iberonewsiberonews.com · 20 Oct 2026Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?insidermonkey.com · 20 Oct 2026Guardant Health, Inc.: Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026finanznachrichten.de · 20 Oct 2026Guardant Health Diagnoses Breakout Move | Investor's Business Dailyinvestors.com · 21 Sep 2026Guardant Health, Shield: Teams up with colon cancer coalition's Get Your Rear in Gear® 5K Run/Walk in Milwaukee to increase colorectal cancer screening awareness and educationwisbusiness.com · 18 Sep 2026Guardant Health Nears Buy Point As Sales Outlook Brightensinvestors.com · 16 Sep 2026Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)yahoo.com · 16 Sep 2026Patrick Dempsey Is the New Face of Guardant Health's 'The Reckoning' Campaignadweek.com · 15 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.